Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zirconium-89 DFO REGN 5054

Next Previous
Drug Profile

Zirconium-89 DFO REGN 5054

Alternative Names: 89Zr-DFO-REGN5054

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Diagnosis, Late-stage disease, Metastatic disease) in Netherlands (IV, Infusion)
  • 08 Mar 2022 Regeneron Pharmaceuticals plans a phase I trial in Solid tumours (Diagnosis, Metastatic disease, Late-stage disease) in June 2022 (IV) (NCT05259709)
  • 07 Feb 2022 Phase-I clinical trials in Solid tumours (Diagnosis, Late-stage disease, Metastatic disease) in Netherlands (IV) (NCT05259709)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top